LNTH
Lantheus Holdings, Inc. NASDAQ Listed Jun 25, 2015$91.01
Mkt Cap $5.9B
52w Low $47.25
95.7% of range
52w High $93.00
50d MA $79.82
200d MA $65.29
P/E (TTM)
24.7x
EV/EBITDA
10.2x
P/B
5.3x
Debt/Equity
0.0x
ROE
21.4%
P/FCF
12.7x
RSI (14)
—
ATR (14)
—
Beta
-0.12
50d MA
$79.82
200d MA
$65.29
Avg Volume
927.0K
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
331 Treble Cove Road · Bedford, MA 01862 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 86.15 | +4.5% | +5.6% | — | — | — | — | — |
| Feb 26, 2026 | AMC | 1.18 | 1.67 | +41.5% | 75.43 | -1.8% | -0.7% | +1.9% | +3.3% | -1.3% | -2.0% | — |
| Nov 6, 2025 | AMC | 1.27 | 1.27 | +0.0% | 53.69 | +1.2% | -4.9% | -0.7% | +5.3% | +2.1% | -2.5% | — |
| Aug 6, 2025 | AMC | 1.64 | 1.57 | -4.3% | 51.87 | +3.4% | +5.8% | +4.3% | -2.0% | -3.9% | -0.2% | — |
| May 7, 2025 | AMC | 1.68 | 1.53 | -8.9% | 80.49 | +1.2% | -0.1% | +1.6% | -2.7% | -0.7% | -0.2% | — |
| Feb 26, 2025 | AMC | 1.58 | 1.59 | +0.6% | 93.25 | -0.9% | -1.9% | +2.5% | +1.1% | +3.5% | +2.4% | — |
| Nov 6, 2024 | AMC | 1.56 | 1.70 | +9.0% | 91.17 | +0.4% | -3.1% | -0.9% | -3.9% | +1.3% | -6.3% | — |
| Jul 31, 2024 | AMC | 1.83 | 1.80 | -1.6% | 104.83 | +0.0% | -5.9% | -1.0% | +1.5% | -0.9% | -2.1% | — |
| May 2, 2024 | AMC | 1.54 | 1.69 | +9.7% | 78.18 | -0.2% | -3.4% | -0.0% | +0.7% | -2.0% | +1.9% | — |
| Feb 22, 2024 | AMC | 1.45 | 1.75 | +20.7% | 65.05 | +0.3% | +1.9% | +2.8% | +0.2% | -4.2% | +0.0% | — |
| Nov 2, 2023 | AMC | 1.32 | 1.47 | +11.4% | 62.16 | +1.8% | +3.5% | +0.2% | +0.9% | -2.5% | -2.1% | — |
| Aug 3, 2023 | AMC | 1.31 | 1.54 | +17.6% | 73.06 | +0.1% | +3.6% | -4.5% | -2.6% | -2.3% | -1.1% | — |
| May 4, 2023 | AMC | 1.29 | 1.47 | +14.0% | 94.86 | +1.4% | -0.8% | +0.8% | +2.6% | +1.7% | +0.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 15 | Truist | Maintains | Buy → Buy | — | $82.74 | $83.23 | +0.6% | +1.5% | -0.0% | -0.1% | +0.2% | -2.9% |
| Apr 13 | Mizuho | Maintains | Outperform → Outperform | — | $80.59 | $79.64 | -1.2% | +1.3% | +1.3% | +1.5% | -0.0% | -0.1% |
| Mar 2 | Truist | Maintains | Buy → Buy | — | $74.91 | $74.58 | -0.4% | +1.9% | +3.3% | -1.3% | -2.0% | -4.9% |
| Feb 27 | Jones Trading | Downgrade | Buy → Hold | — | $75.43 | $74.06 | -1.8% | -0.7% | +1.9% | +3.3% | -1.3% | -2.0% |
| Feb 27 | Mizuho | Maintains | Outperform → Outperform | — | $75.43 | $74.06 | -1.8% | -0.7% | +1.9% | +3.3% | -1.3% | -2.0% |
| Feb 27 | Citizens | Maintains | Market Outperform → Market Outperform | — | $75.43 | $74.06 | -1.8% | -0.7% | +1.9% | +3.3% | -1.3% | -2.0% |
| Feb 24 | Citizens | Maintains | Market Outperform → Market Outperform | — | $73.42 | $73.50 | +0.1% | +0.3% | +2.9% | -0.4% | -0.7% | +1.9% |
| Dec 18 | Truist | Maintains | Buy → Buy | — | $65.24 | $65.50 | +0.4% | -0.6% | +1.7% | +3.2% | -2.2% | +0.2% |
| Dec 17 | Mizuho | Maintains | Outperform → Outperform | — | $65.17 | $65.21 | +0.1% | +0.1% | -0.6% | +1.7% | +3.2% | -2.2% |
| Dec 12 | Truist | Upgrade | Hold → Buy | — | $63.10 | $64.42 | +2.1% | +5.6% | -0.1% | -2.1% | +0.1% | -0.6% |
| Nov 10 | Truist | Maintains | Hold → Hold | — | $51.07 | $51.00 | -0.1% | -0.7% | +5.3% | +2.1% | -2.5% | -0.2% |
| Oct 8 | Goldman Sachs | Downgrade | Buy → Neutral | — | $51.84 | $50.50 | -2.6% | +3.3% | -2.2% | +2.2% | +2.0% | +0.9% |
| Sep 16 | B. Riley Securities | Maintains | Buy → Buy | — | $51.74 | $51.57 | -0.3% | +0.5% | -2.2% | +1.4% | -2.2% | -0.6% |
| Sep 15 | TD Cowen | Maintains | Buy → Buy | — | $52.94 | $52.78 | -0.3% | -2.3% | +0.5% | -2.2% | +1.4% | -2.2% |
| Aug 12 | Truist | Downgrade | Buy → Hold | — | $56.07 | $55.02 | -1.9% | -3.9% | -0.2% | +1.3% | -0.5% | +3.3% |
| Aug 7 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $51.87 | $53.65 | +3.4% | +5.8% | +4.3% | -2.0% | -3.9% | -0.2% |
| Aug 7 | Mizuho | Maintains | Outperform → Outperform | — | $51.87 | $53.65 | +3.4% | +5.8% | +4.3% | -2.0% | -3.9% | -0.2% |
| Jun 23 | B. Riley Securities | Maintains | Buy → Buy | — | $79.19 | $78.78 | -0.5% | +2.0% | +0.2% | -0.5% | +0.2% | +0.9% |
| May 8 | Truist | Maintains | Buy → Buy | — | $80.49 | $81.49 | +1.2% | -0.1% | +1.6% | -2.7% | -0.7% | -0.2% |
| Mar 21 | B. Riley Securities | Maintains | Buy → Buy | — | $98.85 | $97.61 | -1.3% | -1.2% | +1.8% | +0.3% | -1.3% | -1.4% |
| Feb 27 | Truist | Maintains | Buy → Buy | — | $93.25 | $92.39 | -0.9% | -1.9% | +2.5% | +1.1% | +3.5% | +2.4% |
| Jan 14 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $94.65 | $94.58 | -0.1% | -2.1% | +0.9% | -2.0% | -0.1% | +2.8% |
| Nov 8 | Truist | Maintains | Buy → Buy | — | $88.32 | $88.95 | +0.7% | -0.9% | -3.9% | +1.3% | -6.3% | +1.4% |
| Nov 7 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $91.17 | $91.49 | +0.4% | -3.1% | -0.9% | -3.9% | +1.3% | -6.3% |
| Aug 1 | Truist | Maintains | Buy → Buy | — | $104.83 | $104.84 | +0.0% | -5.9% | -1.0% | +1.5% | -0.9% | -2.1% |
| Aug 1 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $104.83 | $104.84 | +0.0% | -5.9% | -1.0% | +1.5% | -0.9% | -2.1% |
| Jul 25 | B. Riley Securities | Maintains | Buy → Buy | — | $113.66 | $114.62 | +0.8% | -0.6% | -0.2% | -1.0% | -1.6% | -4.5% |
| Jul 19 | Jones Trading | Maintains | Buy → Buy | — | $115.74 | $117.06 | +1.1% | +0.9% | -1.8% | +0.7% | -1.6% | -0.6% |
| Jul 11 | Leerink Partners | Maintains | Outperform → Outperform | — | $106.18 | $108.90 | +2.6% | +16.4% | -0.2% | -0.2% | -4.0% | +2.8% |
| Jul 11 | Truist | Maintains | Buy → Buy | — | $106.18 | $108.90 | +2.6% | +16.4% | -0.2% | -0.2% | -4.0% | +2.8% |
| May 3 | Mizuho | Maintains | Buy → Buy | — | $78.18 | $78.00 | -0.2% | -3.4% | -0.0% | +0.7% | -2.0% | +1.9% |
| May 3 | Truist | Maintains | Buy → Buy | — | $78.18 | $78.00 | -0.2% | -3.4% | -0.0% | +0.7% | -2.0% | +1.9% |
| Apr 18 | B. Riley Securities | Maintains | Buy → Buy | — | $61.48 | $62.09 | +1.0% | +1.4% | +2.4% | -1.2% | +2.1% | +1.2% |
| Feb 26 | Truist | Maintains | Buy → Buy | — | $66.27 | $66.20 | -0.1% | +2.8% | +0.2% | -4.2% | +0.0% | -1.1% |
| Feb 23 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $65.05 | $65.27 | +0.3% | +1.9% | +2.8% | +0.2% | -4.2% | +0.0% |
| Jan 10 | B. Riley Securities | Maintains | Buy → Buy | — | $63.07 | $63.64 | +0.9% | -6.0% | -4.1% | -1.1% | -1.7% | -0.1% |
| Nov 3 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $62.16 | $63.29 | +1.8% | +3.5% | +0.2% | +0.9% | -2.5% | -2.1% |
| Oct 4 | Mizuho | Maintains | Buy → Buy | — | $74.65 | $75.09 | +0.6% | -2.9% | -5.6% | +3.6% | -1.1% | +0.7% |
| Oct 4 | Truist | Maintains | Buy → Buy | — | $74.65 | $75.09 | +0.6% | -2.9% | -5.6% | +3.6% | -1.1% | +0.7% |
| Oct 3 | B. Riley Securities | Maintains | Buy → Buy | — | $67.65 | $73.00 | +7.9% | +10.3% | -2.9% | -5.6% | +3.6% | -1.1% |
| Sep 28 | Truist | Maintains | Buy → Buy | — | $65.90 | $65.50 | -0.6% | +5.5% | -0.1% | -2.6% | +10.3% | -2.9% |
| Sep 19 | Truist | Maintains | Buy → Buy | — | $64.10 | $64.10 | +0.0% | -1.4% | -2.0% | -2.7% | +2.6% | +4.5% |
| Sep 15 | Truist | Maintains | Buy → Buy | — | $66.36 | $66.43 | +0.1% | -2.3% | -1.1% | -1.4% | -2.0% | -2.7% |
| Jun 28 | Truist | Maintains | Buy → Buy | — | $84.44 | $84.70 | +0.3% | +0.1% | -1.9% | +1.2% | -0.2% | -1.6% |
| Jun 1 | JMP Securities | Maintains | Market Outperform → Outperform | — | $86.59 | $87.27 | +0.8% | +2.9% | -0.5% | -1.2% | +2.4% | -3.2% |
| May 5 | Mizuho | Maintains | Buy → Buy | — | $94.86 | $96.19 | +1.4% | -0.8% | +0.8% | +2.6% | +1.7% | +0.4% |
| May 5 | Truist | Maintains | Buy → Buy | — | $94.86 | $96.19 | +1.4% | -0.8% | +0.8% | +2.6% | +1.7% | +0.4% |
| May 5 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $94.86 | $96.19 | +1.4% | -0.8% | +0.8% | +2.6% | +1.7% | +0.4% |
| Apr 12 | Truist | Maintains | Buy → Buy | — | $86.35 | $87.37 | +1.2% | -1.0% | +2.1% | +1.6% | +0.6% | +1.8% |
| Mar 8 | JMP Securities | Maintains | Market Outperform → Outperform | — | $72.37 | $74.11 | +2.4% | +4.0% | -2.8% | -2.6% | -0.7% | +3.2% |
No insider trades available.
8-K · 2.02
!! High
Lantheus Holdings, Inc. -- 8-K 2.02: Earnings Results
Lantheus Holdings reported quarterly earnings results, with full financial performance details available in the attached press release that investors should review for operational updates and guidance.
May 7
8-K
Lantheus Holdings, Inc -- 8-K Filing
Lantheus Holdings reported full-year 2025 financial results, demonstrating performance as a leading radiopharmaceutical company focused on diagnostic and therapeutic solutions for clinicians.
Feb 26
Data updated apr 25, 2026 7:33pm
· Source: massive.com